Major differences between eGFR based on cystatin C compared with creatinine were associated with higher rates for all-cause mortality, CV events and kidney failure for outpatients, according to data ...

Uncommon EGFR mutations, such as exon 20 insertions, account for nearly one-third of EGFR-driven NSCLC, complicating treatment strategies due to their diversity and structural challenges. Traditional ...

Having a cystatin C-based eGFR value at least 30% lower than creatinine-based eGFR is associated with increased risks of early death, cardiovascular events, and kidney failure requiring replacement ...

Panelists discuss how EGFR mutation profiling guides targeted first-line NSCLC therapy and shifts care toward precision medicine. Panelists discuss how understanding EGFR mutations has transformed the ...

Serum creatinine-based eGFR used alone overestimates kidney function and can lead to inaccurate dosing of medications in patients with cancer. Among patients with cancer receiving renally cleared ...

Figure 6: Mechanism of Anti-EGFR resistance in head and neck cancer by activation of TLR4-MyD88 signaling. EGFR inhibition by cetuximab prevents Src activation, thus preventing MyD88 degradation, ...

Treatment landscape of EGFR-mutant non–small cell lung cancer has evolved in the most recent years. In the metastatic setting, with combination approaches tested in first-line, whereas in the ...

The recent FDA approval of Lazcluze plus Rybrevant for EGFR-mutant non-small cell lung cancer is a “big deal” for patients, an oncologist said. Patients with EGFR-mutant non-small cell lung cancer ...